Why the study?
Does rivaroxaban prevent death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve compared to warfarin?
Does rivaroxaban prevent death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve compared to warfarin?
Rivaroxaban is noninferior to warfarin for the composite outcome of death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban as alternative to warfarin in this population; extends randomized NOAC data to bioprosthetic mitral valve AF.
In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).
No takes yet. Share an insight, caveat, or question.
Guimarães et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: